LeonaBio (LONA) Preferred Stock Liabilities (2019 - 2020)

LeonaBio's (LONA) quarterly Preferred Stock Liabilities came in at $92.5 million in Q2 2020, up 442.71% on a QoQ basis from $17.1 million in Q4 2019.

LeonaBio (LONA) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends

LeonaBio (LONA) has 2 years of Preferred Stock Liabilities data on file, last reported at $92.5 million in Q2 2020.

On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $92.5 million in Q2 2020; TTM through Jun 2020 was $92.5 million, a N/A change from a year earlier, with the FY2019 full-year figure at $17.1 million, changed N/A from the prior year.
Preferred Stock Liabilities for Q2 2020 stood at $92.5 million, up from $17.1 million in the prior quarter.
Over the last five years, Preferred Stock Liabilities for LONA reached as high as $92.5 million in Q2 2020 and fell as low as $17.1 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	LeonaBio	138.33 Mn	70.65 Mn	-	-

Download Data